Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

ect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted, Sr. Director,

Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com.


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... MA (PRWEB) July 23, 2014 ... medicine transplant therapies are biological, but not magical. ... may seem to treat them as if they ... well as unsanctioned studies that constitute “stem cell ... as an approach to developing new regenerative medicine ...
(Date:7/22/2014)... Researchers from the National Institute of Standards and ... have demonstrated a new design for an atomic ... comb, or a microcomb. , The microcomb clock, ... of the new journal Optica ,* is ... microcomb, and its accurate conversion of optical frequencies ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 CTD Holdings, ... the pharmaceutical, medical device, cosmetics, and other markets, announced ... with a group of qualified private investors led by ... , The transaction involved the signing of ... 1,725,000 shares of Common Stock at a price per ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... Madison University of Wisconsin-Madison researcher Scott Sanders has ... one but a rainbow of colors, and to deliver the ... for scanning objects. , ,Researchers can derive information about a ... system allows them to try a full range of colors ...
... approaching and you're really feeling like a salary increase should ... have a great argument for your boss to get him ... dollars are tight and your boss is pre-disposed (or programmed ... ignore or discount most pay-me-more arguments. , ,So how can ...
... a new biomedical institute on Monday in Milwaukee. ... researchers and companies in southeastern Wisconsin is the goal ... is being established with a $1 million grant from ... Institute for Biomedical and Health Technologies is intended to ...
Cached Biology Technology:Want a raise? Ten best midwest tech salary-increase pitches 2Want a raise? Ten best midwest tech salary-increase pitches 3Want a raise? Ten best midwest tech salary-increase pitches 4Want a raise? Ten best midwest tech salary-increase pitches 5New biomedical institute aims to unite business and academia in SE Wisconsin 2New biomedical institute aims to unite business and academia in SE Wisconsin 3New biomedical institute aims to unite business and academia in SE Wisconsin 4
(Date:7/23/2014)... study of identical twins has found that early reading ... in the journal Child Development , was conducted ... College London. , "Since reading is an ability that ... instruction," according to Stuart J. Ritchie, research fellow in ... study. "Early remediation of reading problems might aid not ...
(Date:7/23/2014)... North Carolina State University shows that urban "heat islands" ... States. One factor is that researchers have found warmer ... gloomy scale insect a significant tree pest ... times more adult gloomy scales on urban trees. , ... the gloomy scale in cities, and now we know ...
(Date:7/23/2014)... tissue samples cultured from cystic fibrosis patients, scientists at ... Lung Institute have shown that a new CF drug ... drug. , The finding, published today in the journal ... CFTR protein becomes unstable and loses its ability to ... drugs. The research offers several insights into how novel ...
Breaking Biology News(10 mins):Stronger early reading skills predict higher intelligence later 2Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... 25, 2012Warner C. Greene, MD, PhDwho directs virology ... the 2012 Alumni Achievement Award from the Washington ... This prestigious award acknowledges outstanding personal achievement ... the Washington University Medical Center. Dr. Greene trained ...
... MEDIA ALERT , "Basic science and clinical medicine ... however aim at improving strategies to manage cancer patients. We ... and efficiently implement them in the clinic." Sherene ... 2012 will focus on four major areas: , ...
... Barbara, Calif.) An international team of researchers has ... happens in virtually every cell of our bodies. ... chains of amino acids assume their specific shapes, hence ... In the human body, proteins fold to become muscles, ...
Cached Biology News:Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award 2Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3In protein folding, internal friction may play a more significant role than previously thought 2